Alzheimer’s, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis, and Parkinson’s are considered diagnoses of exclusion. No single test, blood marker, or imaging scan exists to definitively diagnose them. There are no cures for any of them.

The disease pathologies are linked to misfolded protein aggregates. The etiology of protein aggregates are frustratingly opaque, often described as toxic invaders or the result of sporadic mutations. It creates more questions than answers.

Clinical treatment of neurodegenerative diseases has not kept pace with advances in basic and translational research. This is largely because therapeutic development has remained predominantly brain-centric. Pharmaceutical strategies have traditionally emphasized reductionist approaches aimed at discrete molecular targets such as receptors, enzymes, or ion channels to achieve specific pharmacodynamic effects.

The 2012 discovery of the glymphatic system has provided a new framework to understand brain health. It shows that neurodegenerative disease is rarely just a neuron problem, but rather a failure of a larger, neurovascular-glymphatic unit.

The human brain can be modeled as a self-regulating, biomechanical system analogous to a graphics processing unit (GPU). In this framework, the brain functions as the central processing architecture, while the vascular system provides the essential power supply, delivering oxygen and glucose required for sustained neuronal metabolism. The glymphatic system operates as the thermal regulation and waste-clearance network, maintaining ionic balance and preventing the accumulation of neurotoxic metabolites.

When vascular perfusion is compromised, neuronal energy metabolism declines, leading to reduced synaptic efficiency and impaired cognitive output.

Likewise, dysfunction of the glymphatic system diminishes metabolic clearance, resulting in neuroinflammation and cellular stress which is comparable to thermal overload in an electronic processor.

Collectively, these failures reduce the brain’s computational throughput, manifesting as cognitive impairment and disrupted neuronal signaling or innervation. These symptoms are the hallmarks of neurodegeneration in Alzheimer’s, ALS, Multiple Sclerosis, Parkinson’s, and Dementia.

Conversely, when the neurovascular-glymphatic system functions properly, the brain maintains homeostasis.

In this model, neurodegeneration can be defined as the delta between optimized, homeostatic brain health and dysregulation.